Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response-Reference-Cited by-同舟云学术

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Published:2022-11 Issue:11 Volume:33 Page:1149-1158
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Loibl S.,Schneeweiss A.,Huober J.,Braun M.,Rey J.,Blohmer J.-U.,Furlanetto J.,Zahm D.-M.,Hanusch C.,Thomalla J.,Jackisch C.,Staib P.,Link T.,Rhiem K.,Solbach C.,Fasching P.A.,Nekljudova V.,Denkert C.,Untch M.

Funder

Celgene

Berlin Mathematical School

AstraZeneca

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference29 articles.

1. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N Engl J Med,2018

2. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial;Cortes;Lancet,2020

3. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis;Emens;Ann Oncol,2021

4. Pembrolizumab for early triple-negative breast cancer;Schmid;N Engl J Med,2020

5. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial;Mittendorf;Lancet,2020

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mass Spectrometry-Based Proteomics for Classification and Treatment Optimisation of Triple Negative Breast Cancer;Journal of Personalized Medicine;2024-09-05

2. Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial;Annals of Surgical Oncology;2024-08-17

3. Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer;Current Treatment Options in Oncology;2024-08-15

4. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies;Experimental Hematology & Oncology;2024-08-06

5. Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer;Translational Oncology;2024-08